Buprenorphine: A Comprehensive Guide to OUD Treatment and Pain Management

Buprenorphine is a partial μ-opioid receptor agonist and κ-antagonist with unique pharmacology that makes it a cornerstone of opioid use disorder (OUD) treatment and a valuable option for chronic pain.

Pharmacology Highlights

• Ceiling effect on respiratory depression → safer than full agonists.
• High affinity, slow dissociation → blocks other opioids, long duration (24–72 hours sublingual).
• Partial agonism → less euphoria, lower misuse potential.
• Multiple formulations: Sublingual, buccal, transdermal, implant.

Indications

Opioid Use Disorder (OUD)

• Office-based opioid treatment (OBOT)—DATA 2000 waiver (X-waiver) eliminated in 2023; any DEA-registered prescriber can treat.
• Induction: mild-moderate withdrawal (COWS ≥8–10). Start 2–4 mg, titrate to 8–24 mg/day maintenance.
• Combination buprenorphine/naloxone (Suboxone®, generics)—naloxone deters injection misuse.

Chronic Pain

• Transdermal patch (Butrans®: 5–20 µg/hr weekly) or buccal film (Belbuca®).
• Lower respiratory risk vs. full agonists; useful in opioid-tolerant or high-risk patients.

Side Effects

• Common: constipation, nausea, headache, insomnia, sweating, dry mouth.
• Less common: QT prolongation (high dose), hepatic enzyme elevation, adrenal insufficiency.
• Neonatal abstinence syndrome (NAS) if used in pregnancy—but buprenorphine is preferred over methadone for milder NAS.

Safety and Monitoring

• Baseline: LFTs, drug screen, pregnancy test, PDMP check.
• Counsel on sedation risk with benzodiazepines, alcohol, gabapentinoids.
• Regular pill counts, UDS, PDMP reviews.
• Coordinate with counseling/behavioral health (required per SAMHSA).

Special Populations

• Pregnancy: Buprenorphine monoproduct preferred (avoid naloxone exposure). Continue throughout; do not taper.
• Adolescents: FDA-approved ≥16; off-label younger with specialist.
• Pain + OUD: Split dosing (e.g., 8 mg q12h) or add non-opioid adjuvants.

Common Misconceptions

• "Substituting one addiction for another" → False. Stabilizes brain circuitry, enables recovery.
• "Must taper quickly" → False. Long-term maintenance reduces relapse and mortality.
• "Precipitated withdrawal if fentanyl on board" → Real risk. Wait longer (COWS ≥12–15) or use micro-induction (Bernese method).

Buprenorphine saves lives. Expanding access with compassionate, evidence-based care is a public health imperative.